Cat. No. 2177
Biological ActivityHighly selective NPY Y1 receptor antagonist. Ki values are 25.7, 1420, 2403 and 7100 nM at Y1, Y2, Y4 and Y5 receptors respectively. Devoid of agonist activity at Y4 receptors.
Licensing InformationSold under license
(Modifications: Tyr-9 = Tyr-OMe)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Jois et al (2006) Modeling of neuropeptide receptors Y1, Y4, Y5, and docking studies with neuropeptide antagonist. J.Biomol.Struct.Dyn. 23 497. PMID: 16494499.
Jois and Balasubramaniam (2003) Conformation of neuropeptide Y receptor antagonists: structural implications in receptor selectivity. Peptides 24 1035. PMID: 14499282.
Balasubramaniam et al (2001) Highly selective and potent neuropeptide Y (NPY) Y1 receptor antagonists based on [Pro30, Tyr32, Leu34]NPY(28-36)-NH2 (BW1911U90). J.Med.Chem. 44 1479. PMID: 11334558.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for BVD 10 include:
Demorrow et al (2011) Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion. Physiol Rep 300 C1078. PMID: 21270292.
Do you know of a great paper that uses BVD 10 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: BVD 10, supplier, selective, Y1, antagonists, devoid, Y4, agonists, activity, Neuropeptide, Y, Receptors, NPY, BVD10, neuropeptides, Tocris Bioscience, NPY Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Non-peptide apelin receptor agonistBML 111
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonist
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.